Study to explore the palazestrant-atirmociclib combination in approximately 35 patients with initiation anticipated in H2 2025 Results to inform potential pivotal Phase 3 trial of novel combination in frontline metastatic breast cancer setting Sept. 02, 2025 -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today a

August 28, 2025 ProNephro AKI™ (NGAL), early detection test for Acute Kidney Injury, now commercially available to US Labs through BioPorto’s collaboration with Roche Diagnostics. Collaboration with Roche Diagnostics is first major commercial step to significantly advance adoption of ProNephro AKI across US hospital institutions. August 28 – BioPorto A/S (BioPorto or Company) (CPH:BIOPOR), today announced ProNephro AKI (NGAL), the Company’s test for acute kidney injury, is now commercially avai

Aug. 27, 2025 -- MannKind Corporation (Nasdaq: MNKD) today announced that United Therapeutics Corporation (Nasdaq: UTHR) has exercised its option—granted under the companies’ 2018 license and collaboration agreement—to develop a second dry powder inhalation therapy. The original agreement, which led to U.S. FDA approval of Tyvaso DPI in May 2022, included an option for United Therapeutics to expand the license to include additional active ingredients. Under the terms of the expanded agreement

Aug. 22, 2025 -- ViRx@Stanford, a leading biosecurity and pandemic preparedness initiative, and Fifty1 AI Labs, a subsidiary of Fifty1 Labs, Inc. (OTC: FITY), an innovative AI-driven drug repurposing company, today announced a strategic partnership under the "BE READI!" initiative. This collaboration will leverage Fifty1's advanced AI platform to repurpose existing drugs into potent antiviral therapies, addressing urgent viral threats and enhancing global health security. The partnership posit

Aug. 21, 2025 -- Cube Biotech, a pioneer in membrane protein stabilization and purification, and X-Chem, the global leader in DNA-Encoded Library (DEL) technology and data-driven drug discovery, are proud to announce the successful conclusion of Project DEL-MP. Project DEL-MP was a collaborative initiative demonstrating that copolymer-stabilized membrane proteins are not only suitable for DEL screening, they also open up completely new possibilities for even the most challenging targets. The g

19 August, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Uniphar to manage the distribution of AGAMREE® (vamorolone) in the United Arab Emirates, the Kingdom of Saudi Arabia, Kuwait, Oman and Bahrain, for the treatment of Duchenne muscular dystrophy (DMD) in patients four years of age and older. Sales are expected to begin on a named patient basis in Q1 2026, with broader commercial sales anticipated in late 2026 following market authorization

Acquisition Poised to Accelerate Life-Saving Interventions, Combining Academic Excellence with Real-World Innovation to Address Global Addiction Crises and Unlock Multi-Billion Market Opportunities Aug. 19, 2025 --- Branded Legacy, Inc. (OTC: BLEG), a leading diversified holdings company dedicated to pioneering health and wellness solutions, today announced a groundbreaking strategic partnership between its wholly-owned subsidiary, Bio-Legacy Evaluative Group, and McMaster University, one of t

Retired all principal and accrued interest owed its two senior secured lenders, Resorts World Inc. Pte. Ltd., or RWI, and C.V. Starr and Co., Inc., eliminating all senior secured debt from its balance sheet. Entered into an Asset Purchase Agreement with Celeniv Pte. Ltd., or Celeniv, to monetize Celularity intellectual property assets and eliminate senior secured debt. In connection therewith entered into a License Agreement with Celeniv to license back the intellectual property assets on an exc

Aug. 12, 2025 -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced it has received written agreement regarding a registrational trial design from the U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA) for the Company’s planned clinical trial of AXPAXLI (also known as OTX-TKI) for the treatment of non-proliferative diabetic retinopathy (NPDR). “Securing a Speci

Acquisition Poised to Drive Substantial Shareholder Value Through Innovative Technologies, Projected Multi-Million Revenues, and Strategic Leadership Alignment: Amin Janmohamed Steps Up as CEO and Dr. Kristian Thorlund as Chairman to Spearhead Long-Term Success Aug. 12, 2025 -- via IBN -- Branded Legacy, Inc. (OTC: BLEG), a dynamic diversified holdings company at the forefront of health and wellness innovation, is excited to announce the completion of its game-changing acquisition of Bio Legacy